After metastatic disease win, Merck's Keytruda flunks trial in early stomach cancer

Immune checkpoint inhibitors haven’t had tons of success in stomach cancer. Now, Merck has added one failure to the mix. 

Merck’s Keytruda didn’t move the needle in terms of preventing tumors from returning when used around surgery for resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma, the New Jersey pharma said Tuesday.